Diego Alejandro Molina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diego Alejandro Molina has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Enrique Gómez-Marín
Molecular Parasitology Group (GEPAMOL, for the Term in Spanish), Biomedical Research Center, Faculty of Health Sciences, Universidad del Quindío, Armenia, Colombia
3 shared publications - Cristian Rocha-Roa
Department of Biology, University of Fribourg
2 shared publications - Ailan Farid Arenas
Group of Molecular Parasitology (GEPAMOL), Biomedical Research Center, Faculty of Health Science, University of Quindío, Armenia-Quindio, Colombia
1 shared publication Alejandro Hernández
Grupo GEPAMOL, Centro de Investigaciones Biomédicas, Universidad del Quindio, Armenia, Colombia
1 shared publicationAlejandro Zamora-Vélez
Grupo GEPAMOL, Centro de Investigaciones Biomédicas, Universidad del Quindío, Armenia, 630004, Colombia
1 shared publicationDiego Mauricio Moncada Giraldo
Grupo de Estudio en Parasitología Molecular (GEPAMOL)
1 shared publication
Latest Publications
- Open Access
- 1 August 2021
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 16, 129-139
In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii
- 1 August 2021
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 16, 129-139
Open AccessIn vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii
- Open Access
- 29 November 2018
- Published by Springer Nature in BMC Genomics
- Vol. 19 (1) , 1-18
Protein targets of thiazolidinone derivatives in Toxoplasma gondii and insights into their binding to ROP18
Thiazolidinone derivatives show inhibitory activity (IC50) against the Toxoplasma gondii parasite, as well as high selectivity with high therapeutic index. To disclose the target proteins of the thiazolidinone core in this parasite, we explored in silico the active sites of different T. gondii proteins and estimated the binding-free energy of reported thiazolidinone molecules with inhibitory effect on invasion and replication of the parasite inside host cells. This enabled us to describe some of the most suitable structural characteristics to design a compound derived from the thiazolidinone core. The best binding affinity was observed in the active site of kinase proteins, we selected the active site of the T. gondii ROP18 kinase, because it is an important factor for the virulence and survival of the parasite. We present the possible effect of a derivative of thiazolidinone core in the active site of T. gondii ROP18 and described some characteristics of substituent groups that could improve the affinity and specificity of compounds derived from the thiazolidinone core against T. gondii. The results of our study suggest that compounds derived from the thiazolidinone core have a preference for protein kinases of T. gondii, being promising compounds for the development of new drugs with potential anti-toxoplasmosis activity. Our findings highlight the importance of use computational studies for the understanding of the action mechanism of compounds with biological activity.
- 29 November 2018
- Published by Springer Nature in BMC Genomics
- Vol. 19 (1) , 1-18
Open AccessProtein targets of thiazolidinone derivatives in Toxoplasma gondii and insights into their binding to ROP18
Thiazolidinone derivatives show inhibitory activity (IC50) against the Toxoplasma gondii parasite, as well as high selectivity with high therapeutic index. To disclose the target proteins of the thiazolidinone core in this parasite, we explored in silico the active sites of different T. gondii proteins and estimated the binding-free energy of reported thiazolidinone molecules with inhibitory effect on invasion and replication of the parasite inside host cells. This enabled us to describe some of the most suitable structural characteristics to design a compound derived from the thiazolidinone core. The best binding affinity was observed in the active site of kinase proteins, we selected the active site of the T. gondii ROP18 kinase, because it is an important factor for the virulence and survival of the parasite. We present the possible effect of a derivative of thiazolidinone core in the active site of T. gondii ROP18 and described some characteristics of substituent groups that could improve the affinity and specificity of compounds derived from the thiazolidinone core against T. gondii. The results of our study suggest that compounds derived from the thiazolidinone core have a preference for protein kinases of T. gondii, being promising compounds for the development of new drugs with potential anti-toxoplasmosis activity. Our findings highlight the importance of use computational studies for the understanding of the action mechanism of compounds with biological activity.
- 1 January 2014
- Published by Springer Nature
- p. 301-305
Structural Modeling of Toxoplasma gondii TGME49_289620 Proteinase
- 1 January 2014
- Published by Springer Nature
- p. 301-305
Structural Modeling of Toxoplasma gondii TGME49_289620 Proteinase